Immunocore Limited is a UK-based limited company established in 2007, specializing in research and experimental development within the natural sciences and engineering sectors. Located at 92 Park Drive, Abingdon, OX14 4RY, the company focuses on developing innovative solutions for a range of applications, including vaccine development and biopharmaceutical manufacturing. Immunocore’s core expertise lies in the creation and production of complex biological products, particularly focusing on antibody therapeutics and vaccines. They conduct research and development across various therapeutic areas, including oncology, infectious diseases, and autoimmune disorders. The company’s strategic focus centers on leveraging proprietary technologies and intellectual property to address unmet medical needs. Immunocore operates internationally, with a significant presence in Europe and North America. The company employs a team of scientists and engineers dedicated to advancing scientific discovery and translating research into commercially viable products. Immunocore’s size is estimated to be mid-sized, representing a dedicated team of skilled professionals. The company’s key industry focus includes pharmaceuticals, biotechnology, and related research areas. They are classified as a “type” of company, with services centered on research and experimental development. Immunocore is currently a “active” company, and its “hiring_indicators” suggest a continued commitment to growth and innovation.

Immunocore Limited is a UK-based limited company established in 2007, specializing in research and experimental development within the natural sciences and engineering sectors. Located at 92 Park Drive, Abingdon, OX14 4RY, the company focuses on developing innovative solutions for a range of applications, including vaccine development and biopharmaceutical manufacturing. Immunocore’s core expertise lies in the creation and production of complex biological products, particularly focusing on antibody therapeutics and vaccines. They conduct research and development across various therapeutic areas, including oncology, infectious diseases, and autoimmune disorders. The company’s strategic focus centers on leveraging proprietary technologies and intellectual property to address unmet medical needs. Immunocore operates internationally, with a significant presence in Europe and North America. The company employs a team of scientists and engineers dedicated to advancing scientific discovery and translating research into commercially viable products. Immunocore’s size is estimated to be mid-sized, representing a dedicated team of skilled professionals. The company’s key industry focus includes pharmaceuticals, biotechnology, and related research areas. They are classified as a “type” of company, with services centered on research and experimental development. Immunocore is currently a “active” company, and its “hiring_indicators” suggest a continued commitment to growth and innovation.